Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12003875 | 0.83 | CHKA (0.44) | CHKAALDH1A1NMT1HTR6TNKS | |
| SCHEMBL12003756 | 0.83 | CHKA (0.41) | CHKAALDH1A1NMT1PIK3CGHTR6 | |
| SCHEMBL12004118 | 0.81 | PIK3CG (0.37) | PIK3CGSIK2GRM2 | |
| SCHEMBL12003820 | 0.81 | CHKA (0.44) | CHKANMT1PIK3CGTNKSMELK | |
| SCHEMBL12003792 | 0.80 | CHKA (0.43) | CHKANMT1MELK | |
| SCHEMBL1819798 | 0.80 | CHKA (0.46) | CHKAALDH1A1 | |
| SCHEMBL12003997 | 0.78 | CHKA (0.41) | CHKANMT1PIK3CGMELK | |
| SCHEMBL12004000 | 0.77 | PIK3CG (0.56) | CHKAPIK3CG | |
| SCHEMBL1817823 | 0.77 | PIK3CG (0.36) | PIK3CGSIK2GRM2 | |
| SCHEMBL12004150 | 0.75 | HRH3 (0.40) | CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | claimed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | CHKA 3304/4885ALDH1A1 118/4885NMT1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.